TY - JOUR
T1 - Spermatogonial Stem Cell-Based Therapies
T2 - Taking Preclinical Research to the Next Level
AU - Sanou, Iris
AU - van Maaren, Jillis
AU - Eliveld, Jitske
AU - Lei, Qijing
AU - Meißner, Andreas
AU - de Melker, Annemieke A.
AU - Hamer, Geert
AU - van Pelt, Ans M. M.
AU - Mulder, Callista L.
N1 - Funding Information: This research was funded by ZonMW TAS, grant number 116003002. QL is the recipient of a China Scholarship Council grant (201706300107). Publisher Copyright: Copyright © 2022 Sanou, van Maaren, Eliveld, Lei, Meißner, de Melker, Hamer, van Pelt and Mulder.
PY - 2022/4/4
Y1 - 2022/4/4
N2 - Fertility preservation via biobanking of testicular tissue retrieved from testicular biopsies is now generally recommended for boys who need to undergo gonadotoxic treatment prior to the onset of puberty, as a source of spermatogonial stem cells (SSCs). SSCs have the potential of forming spermatids and may be used for therapeutic fertility approaches later in life. Although in the past 30 years many milestones have been reached to work towards SSC-based fertility restoration therapies, including transplantation of SSCs, grafting of testicular tissue and various in vitro and ex vivo spermatogenesis approaches, unfortunately, all these fertility therapies are still in a preclinical phase and not yet available for patients who have become infertile because of their treatment during childhood. Therefore, it is now time to take the preclinical research towards SSC-based therapy to the next level to resolve major issues that impede clinical implementation. This review gives an outline of the state of the art of the effectiveness and safety of fertility preservation and SSC-based therapies and addresses the hurdles that need to be taken for optimal progression towards actual clinical implementation of safe and effective SSC-based fertility treatments in the near future.
AB - Fertility preservation via biobanking of testicular tissue retrieved from testicular biopsies is now generally recommended for boys who need to undergo gonadotoxic treatment prior to the onset of puberty, as a source of spermatogonial stem cells (SSCs). SSCs have the potential of forming spermatids and may be used for therapeutic fertility approaches later in life. Although in the past 30 years many milestones have been reached to work towards SSC-based fertility restoration therapies, including transplantation of SSCs, grafting of testicular tissue and various in vitro and ex vivo spermatogenesis approaches, unfortunately, all these fertility therapies are still in a preclinical phase and not yet available for patients who have become infertile because of their treatment during childhood. Therefore, it is now time to take the preclinical research towards SSC-based therapy to the next level to resolve major issues that impede clinical implementation. This review gives an outline of the state of the art of the effectiveness and safety of fertility preservation and SSC-based therapies and addresses the hurdles that need to be taken for optimal progression towards actual clinical implementation of safe and effective SSC-based fertility treatments in the near future.
KW - childhood cancer
KW - fertility preservation
KW - fertility restoration
KW - in vitro spermatogenesis
KW - preclinical research
KW - spermatogonial stem cell transplantation
KW - spermatogonial stem cells
KW - testicular grafting
UR - http://www.scopus.com/inward/record.url?scp=85128542370&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fendo.2022.850219
DO - https://doi.org/10.3389/fendo.2022.850219
M3 - Review article
C2 - 35444616
SN - 1664-2392
VL - 13
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 850219
ER -